Introduction
============

Pancreatic carcinoma (PC), \~90% malignantly originated from glandular epithelium of ductal adenocarcinoma, is regarded as the fourth leading cause of cancer-related deaths in the USA and ninth leading cause in China.[@b1-cmar-10-227],[@b2-cmar-10-227] Despite advances in multiple therapies, such as surgery, neoadjuvant chemoradiotherapy, immunotherapies, and so on, it is still a devastating disease, whose 5-year overall survival (OS) is limited to 8%.[@b3-cmar-10-227] Nowadays, surgical resection remains to be considered as the only potentially curative treatment for PC patients. However, only 20% of candidates are suitable for successful resection owing to difficulty in early definite diagnosis.[@b4-cmar-10-227]

According to its dismally malignant behaviors, accurate staging system of PC is essential and needed to counsel patients regarding prognosis appropriately. The American Joint Committee on Cancer (AJCC) 8th staging system of PC is generally based on three factors: tumor size and extent (T), lymph node metastasis (N), and distant metastasis (M), which should be one of the most robust prognostic factors of cancer-specific survival. Reliable confirmation of stage after surgery or at diagnosis is a vital indicator in administrating the following therapeutic strategy.[@b5-cmar-10-227] However, issues on whether non-tumor, node, metastasis (TNM) factors should be added to risk stratification of PC remain controversial. It also shows that the AJCC 8th staging system is deficiently formulated and cumbersome for the prognostic prediction after operative resection.[@b6-cmar-10-227] In addition, the number of positive lymph node metastasis depends on the selection of surgical procedures and circumspective examination of pathologists, which may lead to giant bias and large error in assessing the ability of lymph node metastasis.

In 2004, Berger et al[@b7-cmar-10-227] reported that only lymph node ratio (LNR), the number of positive lymph nodes divided by the total examined lymph nodes, had an impact on OS and disease-free survival in PC patients. In recent years, LNR has been considered as a robust predictor of survival in PC patients better than positive lymph nodes.[@b8-cmar-10-227]--[@b11-cmar-10-227] In addition, non-TNM factors, such as age, grade, serum index, and so on, have also been reported as independent prognostic predictors for survival of PC patients after curative resection.[@b12-cmar-10-227]--[@b14-cmar-10-227] Therefore, a novel staging system breaking through the traditional TNM staging system should be established to assist in risk stratification and survival predictor precisely.

The purpose of this study is to further assess the predictive value of LNR in postoperative PC patients and to formulate a new prognostic model through developing a nomogram. Then, according to the formulated nomogram, a novel nomogram-based staging system was refined and compared with the AJCC 8th staging system.

Methods
=======

Patient population and data source
----------------------------------

The data used in this study were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database registry of National Cancer Institute. All the data accessed from the SEER database were freely available. The selection criteria were as follows: first, the PC patients were selected based on the column of site and morphology for tumor of pancreas (primary site -- labeled): C25.0. Second, according to the *International Classification of Diseases for Oncology* (3rd edition) for tumor of histology/behavior, carcinoma (8010/3), adenocarcinoma (8140/3), and infiltrating duct carcinoma (8500/3) were all included. Another selection criterion was diagnosed from 2010 to 2013 with surgery procedure of pylorus preserving pancreatoduodenectomy (PPPD), Whipple procedure, total pancreatectomy, or extended pancreatoduodenectomy (PD).

The following data were received for each patient: gender, age, grade, liver metastasis, lung metastasis, scope of lymph node surgery, regional lymph node positive, regional lymph node examined, TNM stage, and survival information. The TNM stage of the AJCC 8th edition was evaluated based on the following codes: collaborative stage (CS) tumor size 2004, CS extension 2004, CS lymph nodes 2004, CS metastases at DX 2004, and derived AJCC stage group (7th edition; 2010+). However, patients with unknown characteristics or lack of survival information were excluded in our study. After the inclusion and exclusion criteria, the whole enrolled cohort was considered as the primary cohort. Next, we further randomly select a validation cohort by 1 to 1 ratio as an internal verification. The LNR was calculated with regional lymph node positive divided by regional lymph node examined. This study was approved by the ethics committee of Zhongshan Hospital, Fudan University.

Statistical analysis
--------------------

All statistical analyses and random allocation were performed by SPSS 21.0 statistical package (IBM Corporation, Armonk, NY, USA) and R project version 3.3.3 (<http://www.r-project.org/>) for Windows. The cutoff value of LNR was determined by the receiver operating characteristic (ROC) curve. The OS was compared by Kaplan--Meier curves and analyzed using the log-rank test via GraphPad Prism 6 Software (GraphPad Software Inc., San Diego, CA, USA). The univariate and multivariate analyses and hazard ratios (HRs) were used by Cox proportional hazards regression model to find its independent prognostic risks, and *P* \< 0.05 was considered as statistically significant difference.

A novel prognostic nomogram based on LNR for OS was formulated by the rms package in R project (Bell Laboratories, Murray Hill, NJ, USA). Its predictive performance was measured by concordance index (C-index), calibration curve, and decision curve analysis (DCA) as previously described.[@b6-cmar-10-227] The prognostic prediction was more precise with larger C-index, superior consistency, and wider threshold probability or net benefit. Bootstraps with 1,200 resample in primary cohort or 600 resample in validation cohort were used for such activities. The cutoff value of formulated nomogram staging system was determined by X-tile software. (Yale University, New Haven, CT, USA)

Results
=======

Clinicopathological characteristics
-----------------------------------

From the criteria above, 3,458 patients with histologically confirmed pancreatic head carcinoma from the SEER database were finally included, and the detailed baseline characteristics were displayed in [Table 1](#t1-cmar-10-227){ref-type="table"}. In total, there were 1,760 male and 1,698 female patients with a median age of 67 years (range, 29--95 years) in primary cohort. Approximately 10%, 50%, and 40% of patients suffered from well, moderate, and poor pathological differentiations, respectively. Of the total patients, 68 patients suffered from liver metastasis and 21 patients suffered from lung metastasis. Three hundred sixty-nine, 2,430, 453, and 206 patients underwent PPPD, Whipple procedure, total pancreatectomy, and extended PD, respectively. The median OS was 20 months (range, 1--59 months). In addition, the 1- and 3-year OS rates were 69.6% and 28.5%, respectively. According to the TNM staging system of the AJCC 8th edition, the separate stage of patients was recorded. The clinicopathological characteristics of internal validation cohort randomly selected from primary cohort were displayed in [Table S1](#SD2-cmar-10-227){ref-type="supplementary-material"}.

Correlations between LNR and clinicopathologic characteristics
--------------------------------------------------------------

The median LNR of all enrolled patients was 0.115 (range, 0--1). With the ROC analysis, the optimal cutoff value for LNR was 0.092. The area below the curve was 0.627 (*P* \< 0.001; [Figure S1](#SD1-cmar-10-227){ref-type="supplementary-material"}).

The low-risk cohort (LNR £0.092) and high-risk cohort (LNR \> 0.092) were determined within the primary cohort. High-risk cohort consisted of 54.7% (1,893 of 3,458) in the primary cohort and 54.8% (922 of 1684) in the internal validation cohort, which is displayed in [Tables 1](#t1-cmar-10-227){ref-type="table"} and [S1](#SD2-cmar-10-227){ref-type="supplementary-material"}. Intriguingly, it was statistically significant that LNR was associated with all characteristics except for surgical procedures in the primary cohort. However, in the validation cohort, gender (*P* = 0.001), grade (*P* \< 0.001), lung metastasis (*P* = 0.016), T, N, M classification (all *P* \< 0.001), TNM staging system (*P* \< 0.001), and regional lymph nodes surgery (*P* = 0.023) were confirmed its correlations with LNR. All these analyses indicated no relationships between LNR and the selection of surgical procedures.

Prognostic significance of LNR
------------------------------

As univariate analysis showed, older age (*P* \< 0.001), advanced grade (*P* \< 0.001), liver metastasis (*P* \< 0.001), lung metastasis (*P* = 0.001), higher LNR (*P* \< 0.001), advanced T, N, M classification, and TNM staging system (all *P* \< 0.001) were significantly considered as risk factors in the primary cohort ([Table 2](#t2-cmar-10-227){ref-type="table"}), which was the same as the validation cohort ([Table S2](#SD3-cmar-10-227){ref-type="supplementary-material"}). In multivariate analysis of primary or validation cohort for OS, older age (*P* \< 0.001; HR, 1.331; 95% CI, 1.223--1.448 and *P* \< 0.001; HR, 1.338; 95% CI, 1.184--1.511, respectively), advanced grade (*P* \< 0.001; HR, 1.356; 95% CI, 1.269--1.450 and *P* \< 0.001; HR, 1.408; 95% CI, 1.279--1.550, respectively), advanced T classification (*P* \< 0.001; HR, 1.152; 95% CI, 1.086--1.222 and *P* = 0.001; HR, 1.161; 95% CI, 1.065--1.266, respectively), and elevated LNR level (*P* \< 0.001; HR, 1.563; 95% CI, 1.376--1.776 and *P* \< 0.001; HR, 1.478; 95% CI, 1.237--1.766) remained as independent prognostic indicators. Furthermore, advanced M classification (*P* = 0.003; HR, 2.085; 95% CI, 1.274--3.412) was also verified as an independent survival predictor in the validation cohort ([Table S2](#SD3-cmar-10-227){ref-type="supplementary-material"}).

Through the analysis of Kaplan--Meier curves, LNR larger than 0.092 was significantly associated with poorer OS than low-risk cohort in both primary and validation cohorts ([Figure 1A and B](#f1-cmar-10-227){ref-type="fig"}). In the primary cohort, the 1-, 2-, and 3-year OS rates were 61.8%, 32.0%, and 19.2% in higher LNR cohort and 81.6%, 53.5%, and 39.7% in lower LNR cohort, respectively. The same distinction was exhibited in the validation cohort with 63.7%, 32.9%, and 19.4% in higher LNR cohort and 79.7%, 53.5%, and 39.4% in lower LNR cohort, respectively.

Novel prognostic nomogram for OS prediction
-------------------------------------------

One more accurate prognostic nomogram that integrated age, grade, T classification, and LNR was proposed by multivariate Cox regression models ([Figure 2A](#f2-cmar-10-227){ref-type="fig"}). The C-index for OS prediction with the formulated nomogram was 0.633 (95% CI, 0.6326--0.6334), which was higher than the C-index of TNM staging system (0.583; 95% CI, 0.5826--0.5834) in the primary cohort. The higher C-index, the better predictive accuracy for OS the system achieved. Therefore, the nomogram containing LNR was formulated to predict the survival with superior performance. According to the formulated nomogram, we examined its performance in the validation cohort with C-index of the formulated nomogram (0.630; 95% CI, 0.6291--0.6309) compared to TNM staging system (0.579; 95% CI, 0.5781--0.5799).

As shown in the calibration plot, the observed probability of 1-, 3-, and 5-year OS in the primary cohort and 1- and 3-year OS in the validation cohort showed optimal consistency with the nomogram-predicted OS ([Figure 2B](#f2-cmar-10-227){ref-type="fig"}--[2F](#f2-cmar-10-227){ref-type="fig"}). In DCA, the formulated nomogram yielded preferable net benefit along with a wider field of threshold probability compared to the TNM staging system of the AJCC 8th edition ([Figure 2G--K](#f2-cmar-10-227){ref-type="fig"}), which indicated more robust predictive power for predicting OS at 1, 3, and 5 years. Meanwhile, higher threshold probability represented superior estimations of decision outcomes.

AJCC 8th staging system and survival
------------------------------------

In the primary cohort, 4.08% (141 of 3,458) of patients had stage IV tumors based on the AJCC 8th staging system ([Table 2](#t2-cmar-10-227){ref-type="table"}). The discrimination among stage I, II, and III diseases was not obvious at the beginning of the survival curves, and all these survival curves had the trend in convergence in the end ([Figure 3A](#f3-cmar-10-227){ref-type="fig"}). There were the same shortcomings of the survival curves in the validation cohort ([Figure 3B](#f3-cmar-10-227){ref-type="fig"}). In addition, compared with stage I tumor, the HRs of stage II, III, and IV tumors by univariate analyses according to the AJCC 8th staging system were 1.556, 1.997, and 3.099 in the primary cohort and 1.46, 1.915, and 3.136 in the validation cohort, respectively.

Formulated nomogram staging system and survival
-----------------------------------------------

According to the formulated nomogram, we defined total points not larger than 88 points as stage I disease, larger than 88 points but not larger than 114 points as stage II disease, larger than 114 points but not larger than 169 points as stage III disease, and larger than 169 points as stage IV disease. Through these changes, there were 1,141, 634, 1,569, and 114 patients with stage I, II, III, and IV disease, respectively. On the basis of the new classification, the distinction among stage I, II, and III disease at the beginning or end of the survival curves was larger than that of the AJCC 8th staging system in the primary cohort, so did it in the validation cohort ([Figure 4A and B](#f4-cmar-10-227){ref-type="fig"}). According to the formulated nomogram staging system, survival curves were also separated as better as that in the AJCC 8th staging system between stages, and an obvious increase in HRs was observed with statistical significance. Compared with stage I disease, the HRs of stage II, III, and IV disease by univariate analyses was 1.637, 2.300, and 3.521 in the primary cohort and 1.626, 2.188, and 3.605 in the validation cohort, respectively.

Discussion
==========

In this study, 3,458 total patients with resected pancreatic head carcinoma were finally enrolled and analyzed. Through the analysis of the clinicopathologies, LNR had significant correlations with age, gender, grade, liver or lung metastasis, TNM stage, and regional lymph nodes surgery. However, there was no relationship between LNR and surgery procedures. LNR was confirmed as an independent prognostic risk factor in the univariate and multivariate analyses, so did age, grade, and T classification. Finally, nomogram based on the LNR, age, grade, and T classification was formulated and manifested superior predictive value compared to the AJCC 8th staging system alone. In addition, the formulated nomogram staging system revealed better performance in risk stratification for prognosis of patients with resected pancreatic head carcinoma than the AJCC 8th staging system. All these results were verified in the internal validation cohort.

As we knew, lymph node involvement appeared to be one of the most important risks for predicating OS of resected PC patients.[@b10-cmar-10-227],[@b15-cmar-10-227],[@b16-cmar-10-227] Nevertheless, the total number of examined positive lymph nodes was still imperfect as a pivotal predictor owing to its influence on surgical procedures. We found that LNR did not appear to be associated with surgical procedures, because no matter how expansive of lymph nodes surgery was, LNR reflected its ability in involvement and metastasis, while absolute positive lymph node counts was severely affected by the scope.[@b17-cmar-10-227] In addition, LNR showed excellent discrimination between OS prediction.[@b10-cmar-10-227],[@b18-cmar-10-227]--[@b20-cmar-10-227] Thus, extended lymphadenectomy may not be necessary for PC patients, because it could increase the postoperative complications, morbidities, and mortalities, and even influence the quality of life.[@b21-cmar-10-227],[@b22-cmar-10-227] In general, the assessment of LNR could make patients utmostly benefit from the surgery and still be evaluated accurately on their survival risks, which may guide the following therapies.

As large amounts of factors turned up as prognostic indicators for resected PC patients,[@b23-cmar-10-227]--[@b25-cmar-10-227] the AJCC 8th staging system seemed to lose its powerful efficiency in the evaluation of prognosis. Smith and Mezhir[@b3-cmar-10-227],[@b20-cmar-10-227] established a predictive model of pancreatic cancer patients in 2014, but it was applied in few guidelines or consensuses owing to complexity. Nomogram, a quantitative rating predictive model, had revealed its mighty power in survival prediction, which may have the chance to replace the TNM staging system.[@b26-cmar-10-227] According to this study, age, grade, and T classification (all *P* \< 0.001) besides LNR were also considered as independent prognostic factors. Compared to the AJCC 8th staging system, the concept of tumor size and lymph nodes status were still involving in the formulated nomogram. Besides this, age and differentiation grade were further incorporated into the novel model. Asano et al[@b27-cmar-10-227] had reported the role of age in the survival of resected PC patients. Surgery was considered as a giant damage to patients' physical functions and immune system, which may lead to serious comorbidities and mortalities. In addition, tumor differentiation reflected the biological behaviors of PC, which was highlighted in several studies for its vital role in survival.[@b14-cmar-10-227] Thus, the formulated nomogram merged T, N status and other significant factors together to obtain the much more precise model specially with the validation of superior consistent calibration curves and wider ranges of DCA.

According to the formulated nomogram staging system, the median OS of each stage was 32, 21, 15, and 10 months in the primary cohort compared to 31, 21, 17, and 11 months evaluated by the AJCC 8th staging system. In addition, with the comparison between the nomogram staging system and the AJCC 8th staging system in the primary cohort, we could directly discover that the change in HR for patients in each stage with the nomogram staging system (HRs for stage II, III, and IV, 1.637, 2.300, and 3.521, respectively, with stage I as the reference) was larger than that with the AJCC 8th staging system, so did the discrimination ability in the survival curves (HRs for stage II, III, and IV, 1.556, 1.997, and 3.099, respectively, with stage I as the reference). The same results were verified in the validation cohort. Multiple weaknesses in the AJCC 8th staging system were exposed,[@b5-cmar-10-227] whereas the novel nomogram staging system showed perfect discrimination among each stage.

A limitation of this study was retrospective essentially, so a large-scale and multicenter prospective study should be launched to prove our results and eliminate the selective bias. Next, the cutoff value of LNR used in our study may not be appropriate to other studies, and a meta-analysis containing various LNR validation studies may be required to determine the most suitable cutoff value.

Conclusion
==========

LNR could be a robust prognostic predictor for PC patients with curative resection. The proposed nomogram containing T classification, LNR, age, and grade reveals a superior prognostic model. In addition, the formulated nomogram staging system confirmed its excellent discrimination and risk stratification compared to the AJCC 8th staging system.

Supplementary materials
=======================

###### 

ROC curves for OS.

**Note:** The area under the curve for LNR was 0.627.

**Abbreviations:** LNR, lymph node ratio; OS, overall survival; ROC, receiver operating characteristic.

###### 

Correlations between LNR and clinicopathological characteristics of patients with resected pancreatic head carcinoma in the validation cohort

  Variables                      SEER cohort         
  ------------------------------ ------------- ----- -------------
  Age (years)                                        0.145
   \<70                          452           579   
   ≥70                           310           343   
  Gender                                             **0.001**
   Male                          360           509   
   Female                        402           413   
  Grade                                              \<**0.001**
   Well differentiation          94            88    
   Moderate differentiation      432           456   
   Poor differentiation          236           378   
  Liver metastasis                                   0.127
   Yes                           11            23    
   No                            751           899   
  Lung metastasis                                    **0.016**
   Yes                           0             9     
   No                            762           913   
  T classification                                   \<**0.001**
   T1                            134           102   
   T2                            382           491   
   T3                            96            167   
   T4                            150           162   
  N classification                                   \<**0.001**
   N0                            473           0     
   N1                            284           468   
   N2                            5             454   
  M classification                                   \<**0.001**
   M0                            747           870   
   M1                            15            52    
  TNM staging system                                 \<**0.001**
   I                             335           0     
   II                            262           362   
   III                           150           508   
   IV                            15            52    
  Regional lymph nodes surgery                       **0.023**
   None                          16            15    
   1--3                          35            21    
   ≥4                            711           886   
  Surgery                                            0.616
   PPPD                          85            86    
   Whipple                       533           657   
   Total pancreatectomy          100           129   
   Extended PD                   44            50    

**Note:** Bold figures indicate statistical significant *P*\<0.05.

**Abbreviations:** LNR, lymph node ratio; PD, pancreatoduodenectomy; PPPD, pylorus preserving pancreatoduodenectomy; SEER, Surveillance, Epidemiology, and End Results; TNM, tumor, node, metastasis.

###### 

Univariate and multivariate analyses of prognostic factors associated with overall survival of patients with resected pancreatic head carcinoma in the validation cohort

  Variables                      Overall survival                               
  ------------------------------ ------------------ ------------- ------------- ----------------------
  Age (years)                                       \<**0.001**   \<**0.001**   1.338 (1.184--1.511)
   \<70                          1031                                           
   ≥70                           653                                            
  Gender                                            0.257                       
   Male                          869                                            
   Female                        815                                            
  Grade                                             \<**0.001**   \<**0.001**   1.408 (1.279--1.550)
   Well differentiation          182                                            
   Moderate differentiation      888                                            
   Poor differentiation          614                                            
  Liver metastasis                                  **0.001**     0.987         1.005 (0.585--1.724)
   Yes                           34                                             
   No                            1650                                           
  Lung metastasis                                   **0.024**     0.800         0.904 (0.416--1.967)
   Yes                           9                                              
   No                            1675                                           
  LNR                                               \<**0.001**   \<**0.001**   1.478 (1.237--1.766)
   ≤0.092                        762                                            
   \>0.092                       922                                            
  T classification                                  \<**0.001**   **0.001**     1.161 (1.065--1.266)
   T1                            236                                            
   T2                            873                                            
   T3                            263                                            
   T4                            312                                            
  N classification                                  \<**0.001**   0.128         1.139 (0.963--1.348)
   N0                            473                                            
   N1                            752                                            
   N2                            459                                            
  M classification                                  \<**0.001**   **0.003**     2.085 (1.274--3.412)
   M0                            1617                                           
   M1                            67                                             
  TNM staging system                                \<**0.001**   0.942         0.994 (0.838--1.178)
   I                             335                                            
   II                            624                                            
   III                           658                                            
   IV                            67                                             
  Regional lymph nodes surgery                      0.817                       
   None                          31                                             
   1--3                          56                                             
   ≥4                            1597                                           
  Surgery                                           0.150                       
   PPPD                          171                                            
   Whipple                       1190                                           
   Total pancreatectomy          229                                            
   Extended PD                   94                                             

**Abbreviations:** LNR, lymph node ratio; PD, pancreatoduodenectomy; PPPD, pylorus preserving pancreatoduodenectomy; TNM, tumor, node, metastasis.
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![Kaplan--Meier survival curves for patients according to LNR.\
**Notes:** Patients with LNR larger than 0.092 were inclined to significantly poorer OS in the primary cohort (**A**) and validation cohort (**B**). *P* values were determined by the log-rank test.\
**Abbreviations:** LNR, lymph node ratio; OS, overall survival.](cmar-10-227Fig1){#f1-cmar-10-227}

![Prognostic nomogram, calibration curves, and DCA.\
**Notes:** The nomogram predicts 1-, 3-, and 5-year OS in patients with pancreatic head carcinoma (**A**). The calibration curves predict OS at 1 year (**B**), 3 years (**C**), and 5 years (**D**) in the primary cohort and at 1 year (**E**) and 3 years (**F**) in the validation cohort. The nomogram-predicted OS is plotted on the x axis, and the actually observed OS is plotted on the y axis. DCA depicts the clinical net benefit in pairwise comparisons across the different models. The formulated nomogram is compared with the AJCC 8th staging system in terms of 1- (**G**), 3- (**H**), and 5-year (**I**) OS in the primary cohort and 1- (**J**) and 3-year (**K**) OS in the validation cohort. On DCA, the nomogram showed superior net benefit with a wider range of threshold probabilities compared with AJCC 8th staging system.\
**Abbreviations:** AJCC, American Joint Committee on Cancer; DCA, decision curve analysis; LNR, lymph node ratio; OS, overall survival.](cmar-10-227Fig2){#f2-cmar-10-227}

![Kaplan--Meier survival curves for patients according to the AJCC 8th staging system.\
**Notes:** The discrimination between stage I, II, III, and IV diseases was distributed by the AJCC 8th staging system in the primary cohort (**A**) and validation cohort (**B**). *P* values were determined by the log-rank test.\
**Abbreviation:** AJCC, American Joint Committee on Cancer.](cmar-10-227Fig3){#f3-cmar-10-227}

![Kaplan--Meier survival curves for patients according to the formulated nomogram staging system.\
**Notes:** The discrimination between stage I, II, III, and IV diseases was distributed by the formulated nomogram staging system in the primary cohort (**A**) and validation cohort (**B**). *P* values were determined by the log-rank test.](cmar-10-227Fig4){#f4-cmar-10-227}

###### 

Correlations between LNR and clinicopathological characteristics of patients with resected pancreatic head carcinoma in the primary cohort

  Variables                      SEER cohort          
  ------------------------------ ------------- ------ -------------
  Age (years)                                         **0.024**
   \<70                          898           1158   
   ≥70                           667           735    
  Gender                                              \<**0.001**
   Male                          737           1023   
   Female                        828           870    
  Grade                                               \<**0.001**
   Well differentiation          195           173    
   Moderate differentiation      855           921    
   Poor differentiation          515           799    
  Liver metastasis                                    **0.016**
   Yes                           21            47     
   No                            1544          1846   
  Lung metastasis                                     **0.048**
   Yes                           5             16     
   No                            1560          1877   
  T classification                                    \<**0.001**
   T1                            317           198    
   T2                            791           1004   
   T3                            198           347    
   T4                            259           344    
  N classification                                    \<**0.001**
   N0                            988           0      
   N1                            566           891    
   N2                            11            1002   
  M classification                                    \<**0.001**
   M0                            1529          1788   
   M1                            36            105    
  TNM staging system                                  \<**0.001**
   I                             717           0      
   II                            553           690    
   III                           259           1098   
   IV                            36            105    
  Regional lymph nodes surgery                        \<**0.001**
   None                          32            27     
   1--3                          79            43     
   ≥4                            1454          1823   
  Surgery                                             0.441
   PPPD                          181           188    
   Whipple                       1092          1338   
   Total pancreatectomy          198           255    
   Extended PD                   94            112    

**Note:** Bold figures indicate statistical significant *P*\<0.05.

**Abbreviations:** LNR, lymph node ratio; PD, pancreatoduodenectomy; PPPD, pylorus preserving pancreatoduodenectomy; SEER, Surveillance, Epidemiology, and End Results; TNM, tumor, node, metastasis.

###### 

Univariate and multivariate analyses of prognostic factors associated with overall survival of patients with resected pancreatic head carcinoma in the primary cohort

  Variables                      Overall survival                               
  ------------------------------ ------------------ ------------- ------------- ----------------------
  Age (years)                                       \<**0.001**   \<**0.001**   1.331 (1.223--1.448)
   \<70                          2056                                           
   ≥70                           1402                                           
  Gender                                            0.088                       
   Male                          1760                                           
   Female                        1698                                           
  Grade                                             \<**0.001**   \<**0.001**   1.356 (1.269--1.450)
   Well differentiation          368                                            
   Moderate differentiation      1776                                           
   Poor differentiation          1314                                           
  Liver metastasis                                  \<**0.001**   0.097         1.387 (0.943--2.042)
   Yes                           68                                             
   No                            3390                                           
  Lung metastasis                                   **0.001**     0.701         1.111 (0.650--1.900)
   Yes                           21                                             
   No                            3437                                           
  LNR                                               \<**0.001**   \<**0.001**   1.563 (1.376--1.776)
   ≤0.092                        1565                                           
   \>0.092                       1893                                           
  T classification                                  \<**0.001**   \<**0.001**   1.152 (1.086--1.222)
   T1                            515                                            
   T2                            1795                                           
   T3                            545                                            
   T4                            603                                            
  N classification                                  \<**0.001**   0.545         1.037 (0.922--1.166)
   N0                            988                                            
   N1                            1457                                           
   N2                            1013                                           
  M classification                                  \<**0.001**   0.097         1.343 (0.948--1.902)
   M0                            3317                                           
   M1                            141                                            
  TNM staging system                                \<**0.001**   0.396         1.052 (0.935--1.184)
   I                             717                                            
   II                            1243                                           
   III                           1357                                           
   IV                            141                                            
  Regional lymph nodes surgery                      0.891                       
   None                          59                                             
   1--3                          122                                            
   ≥4                            3277                                           
  Surgery                                           0.134                       
   PPPD                          369                                            
   Whipple                       2430                                           
   Total pancreatectomy          453                                            
   Extended PD                   206                                            

**Abbreviations:** LNR, lymph node ratio; PD, pancreatoduodenectomy; PPPD, pylorus preserving pancreatoduodenectomy; TNM; tumor, node, metastasis.
